Last updated: September 25, 2026
The fixed-dose combination of bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride is marketed in the United States as Pylera, supplied with omeprazole for eradication of Helicobacter pylori infection. Its commercial value is driven less by novel pharmacology than by formulation complexity, manufacturing reliability, adherence, and access to a lower-cost generic product.
The main formulation opportunities are capsule-size reduction, improved swallowability, odor and taste control, dissolution consistency, packaging optimization, and alternative fixed-dose presentations. The largest commercial risk is generic substitution following the expiry of the principal U.S. product patent. Biosimilar risk is not relevant because the product is a small-molecule oral drug, not a biologic.
What is the composition and regulatory status of the combination?
The product combines three active pharmaceutical ingredients:
| Component |
Function in therapy |
Formulation implication |
| Bismuth subcitrate potassium |
Bismuth antimicrobial and mucosal-protective component |
High inorganic load, density and suspension considerations |
| Metronidazole |
Nitroimidazole antibacterial |
Chemical stability, bitter taste and discoloration risks |
| Tetracycline hydrochloride |
Tetracycline-class antibacterial |
Photosensitivity, degradation, metal-ion interaction and moisture-control concerns |
Pylera is an FDA-approved hard gelatin capsule administered with omeprazole. The labeled regimen is three capsules four times daily for 10 days, creating a total of 120 Pylera capsules per course, in addition to omeprazole dosing [1].
The product is approved for treatment of H. pylori infection and reduction of duodenal ulcer recurrence in adults. The FDA-approved product is not a biologic and does not require biosimilar development under the Public Health Service Act.
What excipients are used in the marketed product?
The U.S. prescribing information identifies the Pylera capsule formulation as containing excipients including colloidal silicon dioxide, corn starch, magnesium stearate, sodium lauryl sulfate, and lactose monohydrate. The capsule shell contains gelatin and colorants, including titanium dioxide and iron oxide-based pigments, according to product labeling [1].
The excipient system has several technical roles:
- Colloidal silicon dioxide improves powder flow and reduces cohesion.
- Corn starch contributes to disintegration and bulk.
- Magnesium stearate provides lubrication during encapsulation.
- Sodium lauryl sulfate improves wetting of hydrophobic or poorly wettable components.
- Lactose monohydrate acts as a diluent.
- Gelatin and shell colorants provide the capsule dosage form and product identification.
The combination is technically demanding because the formulation must accommodate three active ingredients with different physical and chemical properties. Excipients must be selected for compatibility with tetracycline, metronidazole and bismuth-containing material, while preserving rapid and reproducible release.
Which excipient strategies offer the strongest commercial opportunity?
The most attractive strategy is not a simple substitution of one filler for another. A differentiated product would need to solve a measurable problem in the current regimen: pill burden, capsule dimensions, adherence, stability, manufacturing cost or supply reliability.
Can capsule-size reduction create a viable product?
Capsule-size reduction is a major opportunity. Three capsules are taken at each administration, four times daily. The regimen creates a substantial adherence burden and increases packaging, shipping and dispensing costs.
Potential approaches include:
- Higher-density granulation to reduce fill volume.
- Roller compaction to improve bulk density and flow.
- Co-processing of diluent and disintegrant systems.
- Optimized particle-size distribution for the active blend.
- Multiparticulate or mini-tablet systems within a capsule.
- A more concentrated capsule strength, subject to bioequivalence and safety requirements.
The principal constraint is the total active mass. Excipients cannot materially reduce the mass of bismuth, metronidazole and tetracycline required for each dose. Capsule-size reduction is therefore more likely to produce incremental improvement than a dramatic reduction in the number of capsules.
What excipients can improve wetting and dissolution?
Sodium lauryl sulfate is already used as a wetting agent in the marketed product. Alternative or supplemental systems could include poloxamers, sodium docusate, or other surfactants permitted for oral solid dosage forms.
The selection must be controlled carefully. Excess surfactant can affect powder flow, capsule-shell integrity, gastrointestinal tolerability and dissolution profiles. The development target should be rapid, reproducible release rather than maximum surfactant loading.
A formulation developer should characterize:
- Dissolution in multiple pH conditions.
- Release after exposure to gastric fluid.
- Impact of food and proton-pump inhibitor coadministration.
- Bismuth dispersion and sedimentation behavior.
- Metronidazole and tetracycline recovery during accelerated stability testing.
How can excipients address metronidazole bitterness and odor?
Metronidazole has a well-known bitter taste, and odor or taste perception can affect adherence if capsule integrity is compromised. The hard gelatin capsule reduces direct exposure, but it does not eliminate the risk from powder leakage, opening, crushing or accidental contact.
Potential strategies include:
- Film-coating individual active particles.
- Microencapsulation of metronidazole.
- Lipid or polymeric taste-masking layers.
- Use of low-permeability capsule shells.
- Moisture-resistant blister packaging.
- Improved capsule-printing and shell-color systems for product identification.
Taste masking has the strongest commercial value in pediatric or geriatric presentations, although tetracycline use and dosing restrictions limit the pediatric opportunity. It may have greater relevance for an alternative formulation intended for patients with swallowing difficulties.
Which excipients can improve chemical stability?
Tetracycline is vulnerable to degradation under certain moisture, light and pH conditions. Tetracycline also has well-established interactions with polyvalent metal ions, including calcium, magnesium, aluminum and iron. These interactions can reduce absorption if the drug is administered with mineral-containing products.
Excipient screening should therefore exclude unnecessary sources of reactive metal ions and assess:
- Water activity.
- Residual moisture.
- Peroxide content in excipients.
- Exposure to light.
- Capsule-shell moisture transfer.
- Compatibility with desiccants and high-barrier packaging.
Low-peroxide grades of excipients may be relevant where oxidative degradation is observed. Packaging can be as important as excipient selection. Alu-alu blisters or high-barrier bottles with desiccant systems may provide a stronger stability advantage than a reformulated bottle package using conventional plastic.
What formulation patents could protect an improved product?
A generic version of the marketed capsule would generally face limited composition-of-matter protection because the active ingredients are established small molecules. Commercial differentiation is more likely through formulation, manufacturing and dosage-regimen claims.
Potential patentable subject matter includes:
- Specific excipient ratios.
- Granulation or compaction processes.
- Particle-size distributions.
- Coated or microencapsulated active particles.
- Reduced-volume capsule fills.
- Moisture-control systems.
- Packaging configurations that preserve stability.
- Modified-release or localized-release systems.
- Alternative dosing schedules supported by clinical data.
- Combination products integrating omeprazole.
Method-of-use patents may cover treatment duration, patient populations, eradication protocols or use after prior treatment failure. Their practical value depends on claim scope, FDA labeling, enforcement cost and whether a generic applicant can carve out the claimed use.
A formulation patent is commercially stronger when it produces an observable performance difference, such as improved stability, a smaller capsule, fewer capsules per dose, or a clinically supported adherence benefit. Narrow claims limited to routine excipient substitutions are more vulnerable to validity and obviousness challenges.
When did Pylera lose U.S. exclusivity?
The principal U.S. patent historically associated with Pylera is U.S. Patent No. 6,893,662, which covers pharmaceutical compositions and treatment approaches involving the combination used for H. pylori therapy. The Orange Book has listed the patent in connection with Pylera, with patent expiry occurring in 2022 after applicable term adjustments and extensions [2].
The FDA product approval itself does not create a permanent barrier to generic entry. New drug application exclusivity and patent protection must be analyzed separately:
| Protection |
Relevance to Pylera |
| New chemical entity exclusivity |
Limited relevance because the product combines known active ingredients |
| Five-year NCE exclusivity |
Not the principal commercial barrier |
| Three-year clinical investigation exclusivity |
Potentially relevant only to qualifying new clinical work |
| Patent protection |
Principal historical barrier |
| Pediatric exclusivity |
May extend listed patent protection where granted |
| Orphan exclusivity |
Not generally applicable |
| Reference-product exclusivity |
Relevant to abbreviated approval timing |
The practical U.S. market question is whether an approved ANDA can launch without infringement exposure from any unexpired listed or non-listed patent. That analysis must include Orange Book patents, formulation patents, method-of-use patents and litigation settlements.
Which companies are challenging or competing with Pylera?
Competition comes from three sources:
- Generic fixed-dose versions of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride.
- Separately dispensed components used with a proton-pump inhibitor.
- Alternative H. pylori regimens, including concomitant, sequential, rifabutin-based and vonoprazan-based therapies.
A generic manufacturer can compete through a capsule that is pharmaceutically equivalent to Pylera or through a therapeutically substitutable regimen using separate products. The fixed-dose product retains a convenience advantage, while separate components may offer lower acquisition cost and greater prescribing flexibility.
The competitive position is affected by regional treatment guidelines and local antibiotic resistance. Metronidazole resistance is particularly relevant to regimen selection. Commercial demand can shift toward alternative regimens if local eradication rates decline.
What is the Paragraph IV risk for this product?
Paragraph IV risk arises when an ANDA applicant certifies that a listed patent is invalid, unenforceable or not infringed. For Pylera, the key exposure historically centered on the composition and treatment patent estate.
A Paragraph IV filing can trigger:
- Notice to the patent holder.
- Hatch-Waxman litigation.
- A potential 30-month stay of ANDA approval.
- Settlement negotiations.
- A possible 180-day first-filer exclusivity period for the first qualifying Paragraph IV applicant.
The value of a Paragraph IV challenge depends on remaining market size, the number of potential entrants, the validity of the listed claims and the possibility of a launch before final judgment. Because the central historical U.S. patent expired in 2022, future generic risk is more likely to concern formulation or manufacturing patents than the original combination patent.
What manufacturing and intellectual-property barriers remain?
The active ingredients are commercially available, but manufacturing is not trivial.
Manufacturing barriers
Key process risks include:
- Uniform distribution of three chemically distinct actives.
- Control of bismuth-containing powder density.
- Segregation during blending and encapsulation.
- Lubricant overmixing and dissolution slowdown.
- Moisture migration through gelatin shells.
- Tetracycline degradation during processing and storage.
- Capsule-fill weight variability.
- Cleaning validation for strongly colored or adhesive powders.
A robust process may require staged blending, controlled particle-size distributions, low-shear lubrication and high-barrier packaging. These process controls can create a practical barrier even where patent protection is weak.
Intellectual-property barriers
The most defensible IP positions are likely to involve:
- A measurable reduction in capsule count.
- A validated stability improvement.
- A specific coated-particle architecture.
- A novel manufacturing process with improved content uniformity.
- A clinically supported regimen or patient population.
- A combination with a defined acid-suppression product.
Trade secrets may protect process parameters more effectively than narrow formulation patents. Manufacturing know-how, supplier qualification and control of specialized coating or granulation equipment can delay entry by less sophisticated competitors.
How large is the commercial opportunity?
Product-level Pylera revenue is not separately disclosed by the sponsor in a consistently reported public segment. The commercial opportunity should therefore be modeled from treated-patient volume, course price, generic penetration and market share rather than from a definitive public revenue figure.
The main revenue scenarios are:
| Scenario |
Commercial effect |
| Branded product retains convenience premium |
Higher price, lower volume after generic entry |
| Authorized generic or branded-generic launch |
Share retention with lower net price |
| Low-cost generic capsule |
Rapid price erosion and payer substitution |
| Smaller or easier-to-swallow formulation |
Potential premium in adherence-sensitive channels |
| Alternative H. pylori regimens gain share |
Structural demand reduction |
| Resistance-driven use of other therapies |
Reduced utilization in selected geographies |
The most attractive product-development opportunity is a lower-pill-burden formulation with demonstrated bioequivalence, strong stability and lower packaging cost. A premium excipient system alone is unlikely to support a large price premium unless it changes administration, tolerability or adherence.
How does this product compare with competing H. pylori regimens?
| Regimen type |
Main advantage |
Main commercial weakness |
| Pylera plus omeprazole |
Fixed-dose convenience and established bismuth-based therapy |
Four-times-daily dosing and high capsule burden |
| Separate bismuth, metronidazole and tetracycline |
Flexible sourcing and potentially lower cost |
More dispensing complexity and adherence risk |
| Concomitant therapy |
Uses widely available agents |
Resistance and tolerability concerns |
| Rifabutin-based therapy |
Option after treatment failure or resistance |
Higher cost and narrower use |
| Vonoprazan-based therapy |
Potent acid suppression and simpler regimens in some markets |
Product access, price and regimen-specific constraints |
Pylera is strongest where prescribers value a recognized bismuth-based fixed-dose regimen. It is weaker where payers prioritize acquisition cost or where newer regimens reduce dosing frequency.
Is there biosimilar risk, licensing activity or settlement exposure?
Biosimilar risk is not applicable. The product is a small-molecule oral combination and faces generic, not biosimilar, competition.
Licensing opportunities may arise around:
- Regional commercialization rights.
- Authorized generic supply.
- Alternative capsule technologies.
- Contract manufacturing.
- High-barrier packaging.
- Reformulated products for markets with different dosing or labeling requirements.
Settlement agreements should be reviewed for launch dates, authorized-generic provisions, royalty terms, covenants not to sue and restrictions on formulation changes. Publicly available information does not establish a current, material settlement structure that independently blocks generic competition across all markets.
Geographic coverage varies. U.S. Orange Book protection does not determine patent status in Europe, Canada, Japan, China or emerging markets. A commercial program requires country-by-country review of composition, formulation, process and method-of-use rights.
Key Takeaways
- The product is Pylera, a fixed-dose oral combination used with omeprazole for H. pylori eradication.
- Its main technical challenges are active-ingredient compatibility, powder uniformity, tetracycline stability, moisture control and capsule burden.
- The highest-value excipient opportunity is a smaller, more stable and easier-to-administer dosage form.
- Taste masking and capsule-shell protection may support differentiated products, particularly for swallowing-sensitive patients.
- The historical U.S. composition patent, U.S. Patent No. 6,893,662, expired in 2022, shifting competitive focus toward generic entry and formulation patents.
- Biosimilar competition does not apply.
- Commercial upside depends on adherence improvement, generic pricing, treatment-guideline adoption and resistance patterns.
- Manufacturing know-how and packaging controls may be more durable competitive assets than narrow excipient patents.
FAQs
Can lactose be replaced in a generic Pylera formulation?
Yes. Lactose may be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate or co-processed excipients, subject to compatibility, dissolution, stability and bioequivalence requirements. The replacement can support a lactose-free product but does not automatically create meaningful market differentiation.
Is a three-in-one tablet commercially feasible?
A tablet is technically possible, but the total active load, bismuth density, compression behavior and tetracycline stability create substantial development challenges. A tablet could reduce capsule count, but it would require comparative dissolution, stability and bioequivalence data.
Can enteric coating improve the product?
An enteric-coated or delayed-release system could alter exposure and tolerability, but it would change the product’s release profile and regulatory pathway. It would require clinical justification rather than simple formulation bridging.
Does coadministration with omeprazole create a combination-product opportunity?
Yes. An integrated pack containing Pylera-equivalent capsules and omeprazole could improve dispensing convenience and adherence. A single dosage form would be more difficult because the release and stability requirements of the antibacterial combination and proton-pump inhibitor may differ.
What is the strongest patent claim for a reformulated product?
A claim tied to a measurable technical result is generally stronger than a claim covering routine excipient substitution. Examples include a defined particle-coating system that improves stability, a reduced-volume composition that preserves dissolution, or a manufacturing process that improves content uniformity.
References
- U.S. Food and Drug Administration. (2022). Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) capsules: Prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Patent No. 6,893,662. (2005). Pharmaceutical compositions and methods for treating Helicobacter pylori infection.
- American College of Gastroenterology. (2024). ACG clinical guideline: Treatment of Helicobacter pylori infection. The American Journal of Gastroenterology.
